Item 2.02 Results of Operations and Financial Condition.

On January 9, 2023, Ironwood Pharmaceuticals, Inc. (the "Company") issued a press release (the "Press Release") containing an update on its recent business activities.

In addition, beginning on January 9, 2023, the Company intends to use the presentation (the "Corporate Presentation") furnished herewith, or portions thereof, which provides updates on the Company's business activities, in one or more meetings with or presentations to investors.

The Press Release and Corporate Presentation contain information regarding certain of the Company's results of operations for 2022. Copies of the Press Release and Corporate Presentation are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference.

The Press Release and Corporate Presentation are being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.





(d)  Exhibits.



Exhibit No.   Description
   99.1         Ironwood Pharmaceuticals, Inc. Press Release dated January 9,
              2023
   99.2         Corporate Presentation
    104       The cover page from this Current Report on Form 8-K, formatted in
              Inline XBRL

© Edgar Online, source Glimpses